Table 1.
Clinical studies testing antioxidant molecules with potential therapeutic value for Alzheimer’s disease treatment. Other: other symptoms or biomarkers evaluated; NT: not tested; U: unspecified; ADAS-Cog: Alzheimer disease assessment scale–cognitive; APS: Alzheimer Progression Score; BADLS: Bristol Activities of Daily Living Scale; CGI-I: Clinical Global Impression-improvement; MMSE: Mini Mental Status Evaluation Test; NPI: Neuropsychiatry Inventory.
| Compound (Dose). | Source | Patients (Years Old) |
Study Design | Inflammatory/AD Biomarkers | Cognitive Effect | Other | Citation Year |
|---|---|---|---|---|---|---|---|
| Naproxen (220 mg/twice daily) |
Derived from propionic acid | 195 (>55) |
2 years | NT | = APS progression | - | [34] 2020 |
| Celecoxib (200 mg/twice daily) |
Derived from propionic acid | 2356 (70–85) |
3 years | NT | = ADAPT score | - | [35] 2015 |
| Etanercept (50 mg/once weekly subcutaneous) |
U | 41 (70–74) |
24 weeks | = TNF-α levels = IL-6 levels = IL-10 levels = IL-12p70 levels = CRP levels |
= ADAS-cog score = BADLS score = CGI-I = Cornell Scale score = MMSE score = NPI score |
- | [36] 2015 |